Somnuek Sungkanuparph, M.D.
|
|
- Osborn Freeman
- 5 years ago
- Views:
Transcription
1 HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor Washington University School of Medicine
2 Goal of Antiretroviral Therapy Relative Levels HIV Viral load <50 copies/ml at 4-6 month CD4 Limit of Detection HAART Years After HIV Infection
3 Evolution of HAART Survival from age 25 years 1 Population controls Probability of Survival Early HAART ( ) Late HAART ( ) 0 Pre-HAART ( ) Age, years Lohse N, et al. Ann Intern Med 2007;146:87-95
4 Can we achieve that goal? Yes. May be. No. What are limitations? 1. Budget 2. Treatment failure 3. Adverse drug effects 4. Opportunistic infections & cancers
5 How Does Resistance Develop? Wrong Dose Host Genetics Poor Potency Social/Personal Issues Regimen Issues Toxicities Poor Adherence Poor Absorption Insufficient Drug Level Rapid Clearance Poor Activation Viral Replication in the Presence of Drug Drug Interactions Resistant Virus Transmission 5
6 Adherence and Drug Resistance
7 Pathogenesis of HIV Drug Resistance K103N L63P Wild-type HIV HIV with mutations Drug resistant HIV Drug susceptible HIV HAART Suboptimal HAART PREDOMINANT WILD-TYPE HIV EARLY EMERGENCE OF RESISTANT HIV PREDOMINANT RESISTANT HIV Baseline 6 Months 9 Months 7 Continuation of a failing ART regimen after early resistance has developed selects for expansion of resistance
8 Definition of Drug Resistance Changes in the viral genetic sequence (mutations) that decrease drug activity. Commonly reduce drug susceptibility compared with the susceptibility of wild-type viruses Mediated by: Changes in the molecular target of therapy Changes in other viral proteins that indirectly interfere with a drug s activity 8
9 HIV Drug Resistance: Implication Resistance mutations may exist before drug exposure and may emerge quickly after drug is introduced. Drugs which develop high level resistance with a single mutation are at greatest risk e.g., 3TC, NNRTIs (nevirapine, efavirenz) Resistance to agents which require multiple mutations will evolve more slowly (e.g. PIs) Partially suppressive regimens will inevitably lead to emergence of resistance A high genetic barrier needs to be set to prevent resistance
10 Genetic Barrier to Drug Resistance Example: GB = 4 VIRAL REPLICATION Remaining Mutations Required For Resistance Mutations Already Selected Concept Dr. J. Shapiro
11 Genetic Barrier to Drug Resistance Example: GB = 1 VIRAL REPLICATION Remaining 1 0 Mutations Required For Resistance Mutations Already Selected Concept Dr. J. Shapiro
12 Post SD-NVP Resistance Mutations Emergence of drug resistance after intrapartum SD-NVP is more common than previously reported Resistance rate at least 65% with real-time PCR assay Rates of 20%-44% for less-sensitive sequence analysis K103N and Y181C are the most common mutations.
13 Acquisition of NVP Resistance in Mothers after SD-NVP for PMTCT DETECTABLE RESISTANCE (%) sd-nvp alone ZDV + sd-nvp >2 ARV + sd-nvp 2 Doses TIME: 6 wk CLADE: B 6 wk E,B 4 wk E,B 6 wk A,D 7 wk B,G,F 4 wk CRF,A 7 wk C 8 wk E,B 4 6 wk C 2 wk C McIntyre J, et al. 12th CROI, Boston 2005, #8. 13
14 Potential Concern When Stopping Drugs With Different Half-liveslives Last Dose Day 1 Day 2+ Drug Concentration Zone of potential replication MONOTHERAPY IC 90 IC Time (Hours) S. Taylor et al. 11th CROI Abs 131
15 Stopping Drugs with Different Half-lives: lives: PI vs. NNRTI NVP spends more time in the zone of potential replication and therefore exerts selective pressure for longer With a low genetic barrier, resistance to NVP develops relatively quickly Last or Single Dose LPV/r Drug Concentration Nevirapine Zone of Potential Replication IC 90 IC 50 0 Days 15 Adapted from Taylor S, et al. 11th CROI 2004, #131.
16 Genetic Barrier and Transmitted Resistance IMPACT OF SINGLE TRANSMITTED MUTATION MUTATIONS REQUIRED FOR RESISTANCE BOOSTED PI NNRTI Activity: Retained Lost Remaining GB: Substantial None Protection of other drugs in regimen: Mostly Retained Lost 16 Concept Dr. J. Schapiro
17 How rapidly is resistance selected? The rate depends on many factors. A potent ART regimen will delay the development of resistance By contrast, an ineffective regimen or inadequate adherence will lead to rapid selection of resistant mutants The replication rate of a resistant variant also influences the rate of its emergence eg, Y181C, and K103N in weeks, high levels of resistance to AZT and PIs in months
18 Resistance is Irreversible Once selected by drug pressure, resistance mutations remain in the viral population Resistance assays commonly detect mutations only if present in >20% of viral population When drug pressure is discontinued, mutations may drop below 20% and not be detected by standard assays Attempts to recycle the drug (or cross-resistant drugs) may result in rapid reappearance (>20%) 18 Johnson et al. XV int. HIV Drug Resistance Workshop, 2006, #69. Palmer et al. PNAS 2006.
19 PI Resistance
20 NRTI and NNRTI Resistance
21 From Codon to Amino Acid: Designations for Mutations Viral DNA is a code for RNA, which in turn codes for protein Each codon encodes a particular amino acid Changes in the codon may result in the incorporation of a different amino acid (mutation) This may be a mechanism for the HIV virus to escape the actions of an ARV drug Codon AAA GAC AGT Mutation AAA AAC AGT Lys Asp Ser Lys Asn Ser 21 Adapted from Winters. Reviewed in Wilson, AIDS Read 2000.
22 How We Identify a Mutation How do we identify a resistance mutation? M 184 M M is the wild type amino acid 184 is the codon position How do we identify a resistance mutation? M 184 V 22 V is the mutant amino acid
23
24 How Can I Know (and Update) the Drug Resistance Mutations? Updates available at
25
26
27
28 RESISTANCE REPORT Resistance-associated RT Mutations: M184V, Y181C Nucleoside and Nucleotide RT Inhibitors Resistance Interpretation zidovudine (AZT) didanosine (ddi) lamivudine (3TC)/emtricitabine (FTC) stavudine (d4t) abacavir (ABC) tenofovir (TDF) Resistance Non-nucleoside RT Inhibitors Resistance Interpretation nevirapine (NVP) efavirenz (EFV) Possible Resistance Resistance
29 RESISTANCE REPORT Resistance-associated PR Mutations: G16E*, K20R*, M36I*, L63P, H69K*, L89M, I93L* Protease Inhibitors Resistance Interpretation saquinavir + ritonavir (SQV/r) indinavir (IDV) IDV/r amprenavir (APV)/fosamprenavir (FPV) APV/r or FPV/r lopinavir + ritonavir (LPV/r) atazanavir (ATV) ATV/r tipranavir + ritonavir (TPV/r) darunavir + ritonavir (DRV/r) Possible Resistance Possible Resistance
30 RESISTANCE REPORT Mutation Details for Nucleoside and Nucleotide RT Inhibitors: lamivudine (3TC)/ Emtricitabine (FTC) M184V indicate Resistance to lamivudine (3TC)/ Emtricitabine (FTC) Mutation Details for Non-nucleoside RT Inhibitors: nevirapine (NVP) Y181C indicate Resistance to nevirapine (NVP) efavirenz (ATV) Y181C indicate Resistance to efavirenz (ATV) Mutation Details for Protease Inhibitors: atazanavir (ATV) G16E, K20R, and M36I indicate Possible Resistance to ATV tipranavir + ritonavir (TPV/r) K20R, M36I, and H69K indicate Possible Resistance to TPV/r Evidence Basis Ia Evidence Basis IIa IIb Evidence Basis IIa IIb
31 RESISTANCE REPORT Evidence Basis I rule based upon 2 or more large, independent virological response studies and supporting in vitro data. II rule based upon in vitro data and preliminary virological response data. III rule based upon in vitro data. No virological response data. IV rule based upon extrapolation of data by the Consensus Panel. Evidence Basis Reference Qualifier a in peer-review journal b at a recognized scientific conference
32
33
34
35
36
37
38 When to Use Resistance Testing (1) IAS-USA [1] DHHS [2] European [3] Thai [4] Primary/acute Recommend Recommend Recommend Post-exposure prophylaxis Recommend Chronic and treatment naïve Consider* Recommend Strongly consider* Failure Recommend Recommend Recommend Recommend Pregnancy Recommend Recommend* Pediatric Recommend *Especially if exposure to someone receiving antiretroviral drugs is likely or if prevalence of drug resistance in untreated patients 5% (European: 10%). 1. Hirsch MS, et al. Clin Infect Dis Available at: 3. Vandamme AM, et al. Antivir Ther Sungkanuparph S, et al. J Med Assoc Thai 2008.
39 Thai HIV Guidelines 2008: When to do genotypic resistance testing? Recommended: - Virological failure during HAART - Suboptimal viral suppression after initiating ART Considered: - HIV infected pregnant women - Acute HIV infection in an area with high prevalence of resistant virus transmission Sungkanuparph S, et al. J Med Assoc Thai 2008.
40 Resistance Mutations After National AIDS Program in Thailand 1,880 patients experiencing treatment failure, during Sukasem C, et al.
41 Thai HIV Guidelines 2008: Recommended First ART Regimens d4t + 3TC + NVP (GPO VIR S ) or AZT + 3TC + NVP (GPO VIR Z ) d4t or AZT + 3TC + EFV Rash, CNS AE d4t or AZT + 3TC + IDV/RTV d4t or AZT + 3TC + LPV/RTV Hyperlipidemia d4t or AZT + 3TC + ATV/RTV Sungkanuparph S, et al. J Med Assoc Thai 2008.
42 Common Resistance Pattern after Failing d4t/ T/3TC/NVP: TC/NVP: Case 1 Resistance-associated RT Mutations: Y181C, M184V, Y188L HIV RNA 9600 copies/ml Nucleoside and Nucleotide RT Inhibitors Resistance Interpretation zidovudine (AZT) didanosine (ddi) lamivudine (3TC)/emtricitabine (FTC) stavudine (d4t) abacavir (ABC) tenofovir (TDF) Resistance Non-nucleoside RT Inhibitors Resistance Interpretation nevirapine (NVP) efavirenz (EFV) Resistance Resistance
43 Common Resistance Pattern after Failing d4t/ T/3TC/NVP: TC/NVP: Case 2 Resistance-associated RT Mutations: Y181C HIV RNA 3200 copies/ml Nucleoside and Nucleotide RT Inhibitors Resistance Interpretation zidovudine (AZT) didanosine (ddi) lamivudine (3TC)/emtricitabine (FTC) stavudine (d4t) abacavir (ABC) tenofovir (TDF) Non-nucleoside RT Inhibitors Resistance Interpretation nevirapine (NVP) efavirenz (EFV) Resistance Resistance
44 Common Resistance Pattern after Failing d4t/ T/3TC/NVP: TC/NVP: Case 3 Resistance-associated RT Mutations: M184V HIV RNA 4100 copies/ml Nucleoside and Nucleotide RT Inhibitors Resistance Interpretation zidovudine (AZT) didanosine (ddi) lamivudine (3TC)/emtricitabine (FTC) stavudine (d4t) abacavir (ABC) tenofovir (TDF) Resistance Non-nucleoside RT Inhibitors Resistance Interpretation nevirapine (NVP) efavirenz (EFV)
45 Common Resistance Pattern after Failing d4t/ T/3TC/NVP: TC/NVP: Case 4 HIV RNA 23,600 copies/ml Resistance-associated RT Mutations: K103N, Y181C, M184V, T215Y Nucleoside and Nucleotide RT Inhibitors Resistance Interpretation zidovudine (AZT) didanosine (ddi) lamivudine (3TC)/emtricitabine (FTC) stavudine (d4t) abacavir (ABC) tenofovir (TDF) Possible Resistance Resistance Possible Resistance Possible Resistance Non-nucleoside RT Inhibitors Resistance Interpretation nevirapine (NVP) efavirenz (EFV) Resistance Resistance
46 Common Resistance Pattern after Failing d4t/ T/3TC/NVP: TC/NVP: Case 5 HIV RNA 51,700 copies/ml Resistance-associated RT Mutations: M41L, A98G, Y181C, M184V, Y188L, T215F Nucleoside and Nucleotide RT Inhibitors zidovudine (AZT) didanosine (ddi) lamivudine (3TC)/emtricitabine (FTC) stavudine (d4t) abacavir (ABC) tenofovir (TDF) Non-nucleoside RT Inhibitors nevirapine (NVP) efavirenz (EFV) Resistance Interpretation Possible Resistance Resistance Possible Resistance Resistance Possible Resistance Resistance Interpretation Resistance Resistance
47 Common Resistance Pattern after Failing d4t/ T/3TC/NVP: TC/NVP: Case 6 Resistance-associated RT Mutations: K103N, F116Y, Q151M HIV RNA 233,000 copies/ml Nucleoside and Nucleotide RT Inhibitors zidovudine (AZT) didanosine (ddi) lamivudine (3TC)/emtricitabine (FTC) stavudine (d4t) abacavir (ABC) tenofovir (TDF) Non-nucleoside RT Inhibitors nevirapine (NVP) efavirenz (EFV) Resistance Interpretation Resistance Resistance Resistance Resistance Resistance Possible Resistance Resistance Interpretation Resistance Resistance
48 Common Resistance Pattern after Failing d4t/ T/3TC/NVP: TC/NVP: Case 7 HIV RNA 121,700 copies/ml Resistance-associated RT Mutations: M41L, K65R, D67N, Y181C, M184V, Y188L, L210W, T215Y Nucleoside and Nucleotide RT Inhibitors zidovudine (AZT) didanosine (ddi) lamivudine (3TC)/emtricitabine (FTC) stavudine (d4t) abacavir (ABC) tenofovir (TDF) Non-nucleoside RT Inhibitors nevirapine (NVP) efavirenz (EFV) Resistance Interpretation Resistance Resistance Resistance Resistance Resistance Resistance Resistance Interpretation Resistance Resistance
49 HIV Drug Resistance Mutations in Patients Failing d4t/ T/3TC/NVPTC/NVP 100% 90% 96% 92% 95% 80% 70% 60% 50% 40% 37% 30% 20% 10% 0% NRTImutation 6% 8% 0 TAMs K65R Q151M M184V/I NNRTImutation PImutation Sungkanuparph S, et al. CID 2007.
50 Resistance mutations conferring to drug resistance Drug Resistance in Patients Failing d4t/ T/3TC/NVPTC/NVP resistance possible resistance 10 0 AZT d4t ddi 3TC ABC TDF NVP EFV Antiretroviral drugs Sungkanuparph S, et al. CID 2007.
51 Drug Resistance Mutations in Patients Failing d4t/3tc/nvp Detection at HIV RNA <4 log vs. >4 log Sungkanuparph S, et al.
52 TAMs and HIV RNA Level at Failure Detection Number of TAMs and HIV RNA levels at failure. a trend toward higher HIV-1 RNA level in patients who had 4 TAMs compared to that in patients without TAMs HIV RNA at virological failure (log copies/ml) P = P = P = P = (p=0.077) or more Number of TAMs Sungkanuparph S, et al. CID 2007.
53 HIV Drug Resistance and Time to Detection of Failure VIROLOGIC FAILURE IMMUNOLOGIC FAILURE CLINICAL FAILURE CD4 COUNT VIRAL LOAD HIV DRUG RESISTANCE 53 Murri R, et al. JAIDS Sungkanuparph S, et al. CID Pillay D, et al. 14th CROI 2007, #642. Losina E et al, 15th CROI 2008, #823
54 Clinical Failure is Just the Tip of the Iceberg Clinical Failure Immunologic Failure CLINICAL EVALUATION only CD4 monitoring Virologic Failure HIV RNA monitoring 54 Murri R, et al. JAIDS. 2006;41: Sungkanuparph S, et al. CID Losina E et al, 15th CROI 2008, #823
55 Failure from 1st Regimen NRTI NNRTI NRTI PI new NNRTI new Class
56 Failure from 2nd Regimen NRTI NNRTI PI new PI new NNRTI new Class
57 When Change of ART Regimen in Treatment Failure is Delayed Accumulates drug resistance mutations More damage to immune system Poorer clinical outcome Higher cost of the effective second regimens More toxicity exposure?
58 Thai HIV Guidelines 2008: Changing ART Regimen after Failure Determine failure with virologic failure only Clarify goals: undetectable vs. maximal virological suppression Review treatment history Assess adherence Accessible HIV genotype resistance testing Identify treatment options Channels for consulting experts Sungkanuparph S, et al. J Med Assoc Thai 2008.
59 Thai HIV Guideline 2008: Recommended Second ART Regimens 2 NRTIs PIs that susceptible indicated by genotypic test LPV/rtv IDV/rtv ATV/rtv SQV/rtv Sungkanuparph S, et al. J Med Assoc Thai 2008.
60 Effective Second-line ART Initiation of effective secondline ART Second-line therapy with a potent, combination ART reduces risk of resistant virus growth
61 Challenges Often Encountered When Treating Patients After Several Regimen Failures Drug resistance to multiple classes and decreased options for the future Accumulative toxicity on multiple drugs Poor adherence on multiple drugs Co-morbidities (if CD4 count low) Multiple drug-drug interactions 61
62 HIV Drug Resistance and Treatment Outcomes of ART Naïve patient Experienced patient Highly Experienced patient Success Failure Success Failure Success Failure
63 Challenges of HIV Treatment in Thailand A huge number of patients who need and will soon need ART Number of patients who need 2 nd ART is increasing Catch up of HIV education with rapid ART scale-up Prevention of HIV drug resistance in all levels is needed Balancing of better lab monitoring (e.g. VL, genotype) and more lab facilities Can we treat earlier (e.g. CD4,350) when we have no third-line in free ART programs?
64 6 ก มภาพ นธ 2553
65 Don't limit your challenges - challenge your limits.
2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationAntiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh
Antiretroviral Prophylaxis and HIV Drug Resistance John Mellors University of Pittsburgh MTN Annual 2008 Outline Two minutes on terminology Origins of HIV drug resistance Lessons learned from ART Do these
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationSasisopin Kiertiburanakul, MD, MHS
What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationPRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES
PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Quebec,
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationThe Use of Resistance Testing in HIV
The Use of Resistance Testing in HIV Dushyantha Jayaweera, M.D., M.R.C.O.G., F.A.C.P. Professor in Clinical Medicine Division of Infectious Diseases University of Miami Miller School of Medicine Viral
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationI m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.
Supplementary Material Appendix 1 Here we show that independent inhibition by a single drug of two distinct steps (A and ) in the viral life cycle results in a non-linear median effect dose-response curve
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationGenotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen
Original Article Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Somnuek Sungkanuparph, M.D.* Weerawat Manosuthi, M.D.* Sasisopin Kiertiburanakul, M.D.* Wasun chantratita, Ph.D.**
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationA Genetic Test to Screen for Abacavir Hypersensitivity Reactions
The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007
More informationAntiviral Therapy 2011; 16: (doi: /IMP1851)
Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationWhen to start, when to switch ART and monitoring of ARV side effects
When to start, when to switch ART and monitoring of ARV side effects Thanomsak Anekthananon, MD Faculty of Medicine Siriraj Hospital September 4, 2009 Recommended Websites Free e-book: HIV Medicine 2007
More informationVirological failure in children. Dr Lee Fairlie
Virological failure in children Dr Lee Fairlie Case 1 Thembi is a 34 year old female. She is HIV infected She lives in JHB and her 2 children, Lerato and Sipho live in Mpumalanga with Gogo They are both
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationHIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe V Kouamou 1, J Manasa 1, D Katzenstein 1, A McGregor 1, CE Ndhlovu 1 & AT Makadzange 1. 1 University of Zimbabwe Introduction
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationKiat Ruxrungtham. Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre
Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre www.iasusa.org; www.aidsinfo.nih.gov; www.clinicaloptions.com; www.clinicaloptions.com/hiv
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationClinical Management of Resistance. AMJ Wensing, MD, PhD
Clinical Management of Resistance AMJ Wensing, MD, PhD Changing treatment paradigm First Line Second Line? New First Line North America Western Europe: Eastern Europe Africa mix South America mix More
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationDIAGNOSING AND MANAGING TREATMENT FAILURE. Dr. Jeremy Nel Department of Infectious Diseases Helen Joseph Hospital
DIAGNOSING AND MANAGING TREATMENT FAILURE Dr. Jeremy Nel Department of Infectious Diseases Helen Joseph Hospital VIRAL LOAD IS EVERYTHING (KINDA ) WHY DOES HIV DEVELOP (SO MUCH) RESISTANCE? Just how much
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationViral Resistance with Topical RT-Microbicides. Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles
Viral Resistance with Topical RT-Microbicides Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles verview What antiretrovirals (ARV) are being considered as candidate microbicides? How
More informationOccupational and Non- Occupational HIV Post-exposure Prophylaxis
Occupational and Non- Occupational HIV Post-exposure Prophylaxis Amy V. Kindrick, MD, MPH National Clinicians Post-Exposure Prophylaxis Hotline (PEPline) University of California, San Francisco San Francisco
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationLa terapia dell infezione da HIV: passato, presente e futuro.
1 st Infectivology Today Paestum (SA) 14-15 maggio 2004 La terapia dell infezione da HIV: passato, presente e futuro. Prof. Adriano Lazzarin Università Vita-Salute San Raffaele, Milano Scuola di Specializzazione
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationEuropean Guidelines. for the Clinical Management and Treatment of HIV Infected Adults
European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005 These Euroguidelines result from the comparison of guidelines from several European countries and from a discussion
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationSim Mayaphi. Medical Virology dept. University of Pretoria / TAD NHLS 10 Jun 2014
Sim Mayaphi Medical Virology dept. University of Pretoria / TAD NHLS 10 Jun 2014 Goals of the programme (2013 SA ARV guidelines public sector) Save lives and improve the quality of life of people living
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More information